Related Experiment Video
Updated: Sep 15, 2025

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
The gap between amyloid pathology and cognition
1Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Abstract:
Nrf2 is a transcription factor critical for protecting the brain against oxidative stress and is decreased in Alzheimer's disease (AD) patients, making it a potential therapeutic target. The Curran lab previously identified a novel regulator, WDR23. Now, in a new study by Liu et al., they demonstrate that knocking out WDR23 in the 3xTg-AD mouse improves spatial working memory, interestingly, while increasing a measure of AD-like pathology. Their work brings up several interesting new questions and adds to a growing body of literature that highlights how the relationship between cognition and amyloid pathology is not as clearcut as once thought.
More Related Videos
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Language and Cognition
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....